Page 3 - Ar T News Today

Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.

Developed by ImmunoAct, IIT Bombay and Tata Memorial Hospital, the therapy has been administered to 15 patients in India. Three of them have successfully achieved cancer remission. Dr Gupta, the first commercial patient to be declared free of cancer, speaks of his experience exclusively to The Indian Express

Upon hearing the phrase ‘cancer treatment’, the first word that can typically spring to mind is chemotherapy – a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.

The FDA suggests people participating in clinical trials with these therapies are monitored for the rest of their lives for any new cancerous cells.

Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply.

By Robb M. Stewart Argonaut Gold's production last year narrowly missed its target after the ramp up of the mine and mill at its flagship Magino operation...

(Article 223-16 of General Regulation of the French financial markets authority)...

Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.

South Korea has issued guidelines to monitor the side effects of the two approved CAR-T therapies – Kymriah from Novartis and Carvykti from Janssen.

CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China's National Medical Products Administration (NMPA) for Yuanruida, a domestic CD19-targeting CAR-T therapy for relapsed/refractory B-Cell Acute Lymphocytic Leukemia.